Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.

•Vaccine-induced immune responses to a single adjuvanted protein are sufficient to elicit protection from a complex pathogen.•RZV stimulates broad, robust and persistent immune responses that include polyfunctional effector and memory T cells.•RZV can overcome immune compromise resulting from age, disease or medication to stimulate protective immune responses.